Safety variables: Adverse events (AE). Measuring time: during the first 6 hours after the first three doses, afterwards at each administration (questioning) until 6 months of treatment or disease progression or death. - Presence of AE (Yes, No), - Type of AE (name of the AE), - Duration (time between beginning and end of the event), - Intensity of AE (mild, moderate, severe), - Relationship of causality (remote, possible, probable, very probable), - Result of AE (recuperate, improvement, persist or sequels), - Attitude concerning the studied treatment (without changes, dose modification, temporal or definitive treatment discontinuation). Vital signs (body temperature in Celsius degrees, heart rate in beats per minute, blood pressure in mmHg and respiratory rate in breaths per minute). Measuring time: before and at 2h, 4h, and 6h after first 3 injections, and at any moment if symptoms until 6 months of treatment or disease progression or death. Anti-IFN alpha and gamma antibodies [by ELISA Technique: Patients develop antibodies (Yes, No)]. Measuring time: before treatment, month 3 and month 6. Therapeutic effect Radiographic response (CT scans, MRI): Response Assessment in Neuro-Oncology (RANO) criteria. Measuring time: Before treatment, 30 days, 3 months, 6 months, 1 year, and whenever it is possible until the end of treatment. For the most aggressive tumors, evaluations could be more frequent. Progression-free survival at 6 and 12 months (PFS-6; PFS-12. Time from the date of inclusion to the date of disease progression). Measuring time: 6 months, 12 months. Survival at 6 and 12 months (SV-6, SV-12. Time from the date of inclusion to the date of death). Measuring time: 6 months, 12 months. Clinical response: RANO criteria (Complete Response, Partial Response, Stable Disease, Progressive Disease). Measuring time: Before treatment, 30 days, 3 months, 6 months, 1 year, and whenever it is possible until the end of treatment. For the most aggressive tumors, evaluations could be more frequent. Time for clinical response (Time from the date inclusion to the date of clinical response [complete, partial, stable]). Measuring time: 30 days, 3 months, 6 months, 1 year, and whenever it is possible until the end of treatment. For the most aggressive tumors, evaluations could be more frequent. Duration of the clinical response (Time from the the date of clinical response to the date of of recurrence or disease progression). Measuring time: Measuring time: 30 days, 3 months, 6 months, 1 year, and whenever it is possible until the end of treatment. For the most aggressive tumors, evaluations could be more frequent. Time until the therapeutic failure (appearance of serious adverse events at any moment or lesion progression). Measuring time: 3 months of treatment. Functional capacity (Karnofsky scale and/or ECOG). Measuring time: Before treatment, fourth week, 3 and 6 months, then annually if treatment continue. Muscular strength evaluation (Scale of Asia). Measuring time: Before treatment, fourth week, 3 and 6 months, then annually if treatment continue. Steroids use (Yes, No). Measuring time: monthly until the end of treatment. Quality of life (EORTC QLQ-C30 questionnaire). Measuring time: Before treatment, fourth week, 3 and 6 months, then annually if treatment continue. Neuropsychological assessment (Test of Beck). Measuring time: Before treatment, fourth week, 3 and 6 months, then annually if treatment continue.